Arrowstreet Capital
CLBT icon

Arrowstreet Capital’s Cellebrite CLBT Stock Holding History

Arrowstreet Capital’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,025,693
Closed -$22.6M – 1835
2024
Q4 		$22.6M Sell
1,025,693
-278,297
-21% -$5.36M 0.02% 566
2024
Q3 		$22M Buy
1,303,990
+637,802
+96% +$9.46M 0.02% 520
2024
Q2 		$7.96M Sell
666,188
-879,624
-57% -$9.83M 0.01% 709
2024
Q1 		$17.1M Buy
1,545,812
+235,216
+18% +$2.4M 0.02% 537
2023
Q4 		$11.3M Buy
1,310,596
+427,507
+48% +$3.32M 0.01% 534
2023
Q3 		$6.76M Buy
+883,089
New +$6.63M 0.01% 608
2022
Q2 		– Sell
-19,811
Closed -$127K – 1254
2022
Q1 		$127K Buy
+19,811
New +$131K ﹤0.01% 1131

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AE
Axon Enterprise Scottsdale, Arizona $19.1M AUM 8.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Arrowstreet Capital's CLBT Position: Q1 2025 in Review

Arrowstreet Capital sold out of Cellebrite (CLBT) in Q1 2025, closing a stake of 1,025,693 shares — an estimated $22.6M sold.

Arrowstreet Capital first reported a position in CLBT in Q1 2022 and held it in 7 quarters. The position peaked at $22.6M in Q4 2024. 199 funds tracked by Wall St. Rank hold CLBT as of Q1 2025.

  • Arrowstreet Capital reported no remaining Cellebrite position as of Q1 2025 after selling out during the quarter.
  • Arrowstreet Capital sold 1,025,693 Cellebrite shares in Q1 2025, an estimated $22.6M.
  • Arrowstreet Capital first reported a position in Cellebrite in Q1 2022 and held it in 7 quarters.
  • Arrowstreet Capital's Cellebrite position peaked at $22.6M in Q4 2024.
  • 199 funds tracked by Wall St. Rank held Cellebrite as of Q1 2025.

Based on Arrowstreet Capital's 13F filing for Q1 2025, filed 14 May 2025.